Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRI-601
- Development stage
- Preclinical
- Lead developer
- BRI Pharma
- Modality
- Small Molecules
01
Overview
BRI-601 is a small-molecule inhibitor of Fatty Acid Binding Protein 7 (FABP7) being developed by BRI Pharma for the treatment of neurodegenerative diseases, including Multiple System Atrophy (MSA), Multiple Sclerosis (MS), and Dementia with Lewy Bodies (DLB). The drug works by inhibiting the aggregation of alpha-synuclein in oligodendroglial cells, which is a key pathological feature of these conditions. Preclinical studies have demonstrated that BRI-601 has a wide safety margin and effective brain penetration, supporting its potential as a therapeutic agent for brain inflammatory and neurodegenerative disorders.
02
Targets
FABP7 (Fatty acid-binding protein 7)
Beyond the preview
Go deeper on BRI-601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRI-601.